Toremifene

Toremifene (Fareston, Orion Corporation) has 1 EU-approved indication in 1 tumour type. It needs a biomarker result: Hormone receptor (1).
Approved indications of Toremifene
Biomarker requirementRegimenSettingConditions
Breast cancer1
Hormone receptor-positive
Monotherapy
1L
metastatic
Postmenopausal
Full text of section 4.1 (therapeutic indications)

First line hormone treatment of hormone-dependent metastatic breast cancer in postmenopausal patients. Fareston is not recommended for patients with estrogen receptor negative tumours.

Label history

28 changes to the Fareston label since 1996, none of them to the indications. Newest first, in the words of EMA's record of each procedure.

Changes